TL;DR
For couples where one partner has HSV, three tools measurably lower transmission risk: daily suppressive antiviral therapy (roughly 50% fewer infections, up to 75% fewer symptomatic ones), consistent condom use (26% to over 90% reduction depending on consistency), and avoiding sex during a prodrome or outbreak. None of these, alone or combined, brings risk to zero.
Key Takeaways
- Daily suppressive valacyclovir cut the risk of a partner acquiring symptomatic HSV-2 by about 75% and overall acquisition by about 48% in a large randomized trial of discordant couples.
- Consistent condom use was linked to a 91.5% reduction in HSV-2 acquisition for female partners in one landmark study, though effect sizes vary across studies depending on how consistently condoms were used.
- Avoiding sex only during visible outbreaks or a recognized prodrome addresses a minority of risk: about 70% of documented transmissions happened when the source partner had no symptoms at all.
- No study has tested antivirals, condoms, and symptom-avoidance together in one trial, but each has independent evidence, which is why clinicians generally recommend layering all three rather than relying on just one.
- Risk reduction is real and substantial, but every study in this area reports a remaining risk above zero, even with every precaution in place.
Couples navigating a herpes diagnosis on one side often land on a version of the same question: how careful do we actually have to be, and does it even work? It’s a fair question, and one that deserves real numbers rather than reassurance alone.
The honest answer is that several tools do measurably lower risk, each backed by its own body of research, but none of them, individually or stacked together, has been shown to eliminate risk entirely. That distinction matters. Understanding roughly how much each tool helps, and why even the best combination still leaves some risk on the table, tends to lead to steadier decision-making than either extreme, treating the diagnosis as catastrophic or assuming precautions make risk disappear.
This guide walks through what the research shows for three specific strategies, daily suppressive antiviral therapy, condoms and barrier methods, and avoiding contact during a prodrome or active outbreak, along with how these strategies work together and why “close to zero” is a more accurate goal than “zero.”
Why Doesn’t Any Single Method Reach Zero Risk?
The core reason sits in how HSV actually behaves between outbreaks. A landmark study that followed 144 heterosexual couples where one partner had genital herpes found that transmission occurred even when the source partner reported no symptoms at the time. In fact, about 70% of documented transmissions in that study resulted from sexual contact during periods when the infected partner was showing no visible signs at all, a pattern called asymptomatic viral shedding (Mertz et al., 1992, doi:10.7326/0003-4819-116-3-197). A smaller number of transmissions occurred during the prodrome, the tingling or itching sensation that can precede a visible sore by hours, before any lesion was noticeable.
This is the mechanism that limits every prevention strategy. Antivirals reduce how often and how much the virus sheds, and condoms reduce skin-to-skin contact, but neither can fully account for shedding that neither partner can see or feel coming. That is also why “we only avoid sex during outbreaks” is a meaningfully incomplete strategy on its own, since it only addresses the minority of transmission events.
How Much Does Each Prevention Strategy Actually Reduce Risk?
Three strategies have been studied directly, each with a different evidence base and a different degree of protection.
Daily Suppressive Antiviral Therapy
In a randomized, placebo-controlled trial of 1,484 monogamous, HSV-2-discordant couples, the partner with HSV-2 took either 500 mg of valacyclovir once daily or a placebo for eight months. Among susceptible partners, clinically symptomatic HSV-2 developed in 4 of 743 people in the valacyclovir group compared with 16 of 741 in the placebo group, a 75% relative reduction in symptomatic transmission. Overall HSV-2 acquisition, including cases without symptoms, was 1.9% in the valacyclovir group versus 3.6% in the placebo group, a 48% relative reduction. The trial also measured viral shedding directly: HSV DNA was detected in genital secretions on 2.9% of days for partners on valacyclovir, compared with 10.8% of days for partners on placebo (Corey et al., 2004, doi:10.1056/NEJMoa035144).
Condoms and Barrier Methods
The most cited study on this question followed 528 monogamous, HSV-2-discordant couples for 18 months. Condom use during more than 25% of sex acts was associated with a 91.5% reduction in HSV-2 acquisition for female partners (adjusted hazard ratio, 0.085), though the protective effect for male partners in this particular study was not statistically significant (Wald et al., 2001, doi:10.1001/jama.285.24.3100). A separate, larger study of 1,843 participants found a more modest but still significant dose-response effect: each increase in condom-use frequency category was associated with a 26% lower risk of HSV-2 acquisition overall (Wald et al., 2005, doi:10.7326/0003-4819-143-10-200511150-00007). A case-crossover analysis pooling six studies reinforced this pattern from another angle: each unprotected sex act carried a small but real increase in acquisition odds, while protected acts showed no measurable increase at all (Stanaway et al., 2012, doi:10.1097/OLQ.0b013e318248aa8a).
Avoiding Contact During Prodrome or Outbreak
Recognizing and avoiding sex during a prodrome or visible outbreak still matters, since it addresses a real share of transmission risk. But on its own, this strategy has a hard ceiling: since roughly 70% of transmissions in the classic discordant-couples study occurred during asymptomatic shedding, symptom-avoidance alone leaves the majority of risk unaddressed (Mertz et al., 1992). It works best as one layer among several, not a standalone plan. For more on why herpes can transmit without any visible symptoms, the shedding mechanism is covered in more depth elsewhere on this site.
| Strategy | Measured Risk Reduction | Study | Population |
|---|---|---|---|
| Daily suppressive valacyclovir | ~75% fewer symptomatic infections; ~48% fewer infections overall | Corey et al., 2004 (NEJM) | 1,484 discordant couples, 8-month RCT |
| Condoms, used in more than 25% of sex acts | ~91.5% reduction (female partners) | Wald et al., 2001 (JAMA) | 528 discordant couples, 18 months |
| Condoms, any increase in use frequency | ~26% reduction per category of increased use | Wald et al., 2005 (Ann Intern Med) | 1,843 participants |
| Avoiding sex during prodrome/outbreak alone | Addresses roughly 30% of transmission risk; ~70% of transmissions occur with no symptoms present | Mertz et al., 1992 (Ann Intern Med) | 144 discordant couples |
How Do These Strategies Combine?
No single trial has tested antivirals, condoms, and symptom-avoidance together as one combined intervention, so there is no single published percentage for “all three at once.” What the research does show is suggestive: in the same 528-couple study that measured condom effectiveness, the overall transmission rate fell from 8.5 per 100 person-years early in the study to 0.9 per 100 person-years later on, a period that coincided with declining sexual activity and fewer sex acts occurring while the source partner had visible lesions (Wald et al., 2001). That pattern, several precautions moving in the same direction at once, is consistent with layered protection, even without a formal combined-effect trial.
This is why clinicians generally recommend using more than one strategy rather than picking a single favorite. Each tool addresses a different part of the transmission picture: antivirals reduce how often the virus sheds in the first place, condoms reduce skin-to-skin contact when shedding does occur, and symptom-avoidance removes the highest-risk days entirely. Layering them narrows the gap, without closing it. A related guide on supporting a partner through a new HSV diagnosis covers how couples typically build this kind of plan together.
Frequently Asked Questions
Can a couple with one HSV-positive partner ever have zero risk of transmission?
No study has shown zero risk with any combination of precautions. Every trial in this area, even with daily antivirals and consistent condom use together, reports some remaining rate of transmission over time. The realistic goal is substantially lower risk, not the complete elimination of it.
Is daily antiviral therapy only useful for the partner who has HSV?
The antiviral is taken by the partner who has HSV, but its benefit is measured in the susceptible partner: fewer days of viral shedding translates directly into a lower chance of the other partner acquiring the virus. It is a shared-risk decision even though only one partner takes the medication.
Do condoms protect against herpes the same way they protect against other STIs?
Not entirely. HSV spreads through skin-to-skin contact, and condoms don’t cover every area where that contact can happen, which is part of why condom studies show a real but incomplete reduction in risk rather than near-total protection, as is sometimes seen with infections spread only through fluids.
How do you know when a prodrome is starting?
A prodrome often feels like tingling, itching, or mild discomfort at the site where outbreaks typically occur, sometimes hours before any visible sign appears. People who have had outbreaks before often learn to recognize their own early pattern, which is part of why avoiding sex during a recognized prodrome is still a meaningful precaution, even though it cannot catch shedding with no warning signs at all.
Does having a lower outbreak frequency also lower transmission risk?
Indirectly, yes. Fewer outbreaks generally track with less frequent viral shedding overall, which is part of the same mechanism daily suppressive therapy works through. It is not a substitute for antivirals or condoms on its own, but it is consistent with the same underlying biology.
Summary
Three tools have real, separately measured evidence behind them: daily suppressive antiviral therapy cuts transmission roughly in half to three-quarters depending on how it’s measured, condoms reduce risk by a wide range depending on consistency of use, and avoiding sex during a recognized prodrome removes some of the highest-risk moments. None of them, alone, addresses the majority of risk, since most transmission happens without any symptom to react to.
Used together, these strategies represent the most evidence-based approach available for discordant couples, even without a single trial that measured all three combined. The honest framing is layered protection, not a guarantee. Some people also build general immune-supportive habits into this plan, such as monolaurin, used as a complementary, non-curative part of an overall routine rather than a substitute for the strategies above, available through Shop Monolaurin. For couples working through what a diagnosis means for the relationship itself, this guide addresses the fear of “guaranteed” transmission directly.
Continue Exploring
- Can You Transmit Herpes Without Visible Symptoms?
- My Partner Was Diagnosed With Herpes: How to Support Them and What to Do Next
- Dear Taylor: Am I Guaranteed to Get Herpes If I Stay With Him?
References
- Mertz, G.J. et al., “Risk factors for the sexual transmission of genital herpes,” Annals of Internal Medicine, 1992. https://doi.org/10.7326/0003-4819-116-3-197
- Corey, L. et al., “Once-daily valacyclovir to reduce the risk of transmission of genital herpes,” The New England Journal of Medicine, 2004. https://doi.org/10.1056/NEJMoa035144
- Wald, A. et al., “Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women,” JAMA, 2001. https://doi.org/10.1001/jama.285.24.3100
- Wald, A. et al., “The relationship between condom use and herpes simplex virus acquisition,” Annals of Internal Medicine, 2005. https://doi.org/10.7326/0003-4819-143-10-200511150-00007
- Stanaway, J.D. et al., “Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition,” Sexually Transmitted Diseases, 2012. https://doi.org/10.1097/OLQ.0b013e318248aa8a
